Clinical Trial Detail

NCT ID NCT02706353
Title APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

APX005M + Pembrolizumab

Age Groups: adult

No variant requirements are available.